Publications
-
- Conference presentation
- [ADA 2023] Differentiated Metabolic Effects of DA-1726, a Balanced GLP1R/GCGR Dual Agonist
-
- Conference presentation
- [AACR 2023] A novel AhR inhibitor ‘DA-4505’ enhanced the anti-cancer efficacy in combination with surgery, chemotherapy and pembrolizumab through increasing cytotoxic effects with antigen presentation.
-
- Conference presentation
- [AACR 2023] DA-4505, a novel small-molecule AhR antagonist, as a new therapeutic option of immunotherapies.
-
- Conference presentation
- [AD/PD 2023] Neuroprotective effect of DA-7503, a novel tau aggregation inhibitor, against okadaic acid-induced tauopathy in vitro and in vivo.
-
- Conference presentation
- [SITC 2022] Antitumor effect of DA-4507, a novel GCN2 inhibitor as an immunotherapy in the tumor microenvironment.
-
- Conference presentation
- [AAIC 2022] Discovery of DA-7503 as a novel tau-targeted therapeutic candidate for the treatment of AD.
-
- Conference presentation
- [ADA 2022] Therapeutic Potential of DA-1726, a Novel Oxyntomodulin Analogue, in a Diet-Induced NASH Mouse Model
-
- Conference presentation
- [ADA 2022] DA-1726, a Balanced GLP1R/GCGR Dual Agonist, Effectively Controls both Body Weight and Blood Glucose
-
- Conference presentation
- [EASD 2021] DA-1241 a novel GPR119 Agonist Data on Safety, Tolerability and Pharmacokinetics (PK), from Part 1 of a Phase 1b Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HV)
-
- Conference presentation
- [EASD 2021] DA-1241 a novel GPR119 Agonist: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics - Part 2 of Multiple Ascending Dose Study in Type 2 Diabetes Patients